WO2022002281A1 - 一种血管支架 - Google Patents
一种血管支架 Download PDFInfo
- Publication number
- WO2022002281A1 WO2022002281A1 PCT/CN2021/112630 CN2021112630W WO2022002281A1 WO 2022002281 A1 WO2022002281 A1 WO 2022002281A1 CN 2021112630 W CN2021112630 W CN 2021112630W WO 2022002281 A1 WO2022002281 A1 WO 2022002281A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- braided
- wire
- self
- diameter
- expanding
- Prior art date
Links
- 230000002792 vascular Effects 0.000 title claims abstract description 58
- 210000004204 blood vessel Anatomy 0.000 claims abstract description 21
- 238000009954 braiding Methods 0.000 claims abstract description 18
- 239000000463 material Substances 0.000 claims description 41
- BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Chemical compound [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 claims description 29
- 239000011248 coating agent Substances 0.000 claims description 13
- 238000000576 coating method Methods 0.000 claims description 13
- 229910052697 platinum Inorganic materials 0.000 claims description 13
- 229910001000 nickel titanium Inorganic materials 0.000 claims description 11
- 229910052715 tantalum Inorganic materials 0.000 claims description 9
- GUVRBAGPIYLISA-UHFFFAOYSA-N tantalum atom Chemical compound [Ta] GUVRBAGPIYLISA-UHFFFAOYSA-N 0.000 claims description 9
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 claims description 7
- 229910052737 gold Inorganic materials 0.000 claims description 7
- 239000010931 gold Substances 0.000 claims description 7
- BQCADISMDOOEFD-UHFFFAOYSA-N Silver Chemical compound [Ag] BQCADISMDOOEFD-UHFFFAOYSA-N 0.000 claims description 6
- WAIPAZQMEIHHTJ-UHFFFAOYSA-N [Cr].[Co] Chemical class [Cr].[Co] WAIPAZQMEIHHTJ-UHFFFAOYSA-N 0.000 claims description 6
- 229910045601 alloy Inorganic materials 0.000 claims description 6
- 239000000956 alloy Substances 0.000 claims description 6
- 239000012620 biological material Substances 0.000 claims description 6
- 229910052741 iridium Inorganic materials 0.000 claims description 6
- GKOZUEZYRPOHIO-UHFFFAOYSA-N iridium atom Chemical compound [Ir] GKOZUEZYRPOHIO-UHFFFAOYSA-N 0.000 claims description 6
- 229910052709 silver Inorganic materials 0.000 claims description 6
- 239000004332 silver Substances 0.000 claims description 6
- 230000002785 anti-thrombosis Effects 0.000 claims description 5
- 239000003814 drug Substances 0.000 claims description 5
- 229940079593 drug Drugs 0.000 claims description 5
- 239000003146 anticoagulant agent Substances 0.000 claims description 4
- 229910000531 Co alloy Inorganic materials 0.000 claims description 3
- QXZUUHYBWMWJHK-UHFFFAOYSA-N [Co].[Ni] Chemical compound [Co].[Ni] QXZUUHYBWMWJHK-UHFFFAOYSA-N 0.000 claims description 3
- 229910001220 stainless steel Inorganic materials 0.000 claims description 3
- 239000010935 stainless steel Substances 0.000 claims description 3
- 238000009941 weaving Methods 0.000 abstract description 2
- 238000001356 surgical procedure Methods 0.000 abstract 1
- 206010002329 Aneurysm Diseases 0.000 description 10
- 208000027418 Wounds and injury Diseases 0.000 description 7
- 238000010521 absorption reaction Methods 0.000 description 7
- 201000008450 Intracranial aneurysm Diseases 0.000 description 5
- 238000011161 development Methods 0.000 description 5
- 239000013013 elastic material Substances 0.000 description 5
- 229910052751 metal Inorganic materials 0.000 description 4
- 239000002184 metal Substances 0.000 description 4
- 241000251468 Actinopterygii Species 0.000 description 3
- 210000001367 artery Anatomy 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 230000003446 memory effect Effects 0.000 description 3
- 238000012800 visualization Methods 0.000 description 3
- 210000001841 basilar artery Anatomy 0.000 description 2
- 238000010586 diagram Methods 0.000 description 2
- 238000007917 intracranial administration Methods 0.000 description 2
- 238000000034 method Methods 0.000 description 2
- HLXZNVUGXRDIFK-UHFFFAOYSA-N nickel titanium Chemical compound [Ti].[Ti].[Ti].[Ti].[Ti].[Ti].[Ti].[Ti].[Ti].[Ti].[Ti].[Ni].[Ni].[Ni].[Ni].[Ni].[Ni].[Ni].[Ni].[Ni].[Ni].[Ni].[Ni].[Ni].[Ni] HLXZNVUGXRDIFK-UHFFFAOYSA-N 0.000 description 2
- 206010065559 Cerebral arteriosclerosis Diseases 0.000 description 1
- 208000032170 Congenital Abnormalities Diseases 0.000 description 1
- 238000012276 Endovascular treatment Methods 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- 208000032851 Subarachnoid Hemorrhage Diseases 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 238000002583 angiography Methods 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 208000010353 central nervous system vasculitis Diseases 0.000 description 1
- PRQRQKBNBXPISG-UHFFFAOYSA-N chromium cobalt molybdenum nickel Chemical compound [Cr].[Co].[Ni].[Mo] PRQRQKBNBXPISG-UHFFFAOYSA-N 0.000 description 1
- 210000000275 circle of willis Anatomy 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 230000010102 embolization Effects 0.000 description 1
- 238000003384 imaging method Methods 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 201000005851 intracranial arteriosclerosis Diseases 0.000 description 1
- 230000002601 intratumoral effect Effects 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012856 packing Methods 0.000 description 1
- 238000007634 remodeling Methods 0.000 description 1
- 229910001285 shape-memory alloy Inorganic materials 0.000 description 1
- 230000008733 trauma Effects 0.000 description 1
- 238000011282 treatment Methods 0.000 description 1
- 239000000602 vitallium Substances 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F2/00—Filters implantable into blood vessels; Prostheses, i.e. artificial substitutes or replacements for parts of the body; Appliances for connecting them with the body; Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
- A61F2/82—Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
- A61F2/86—Stents in a form characterised by the wire-like elements; Stents in the form characterised by a net-like or mesh-like structure
- A61F2/90—Stents in a form characterised by the wire-like elements; Stents in the form characterised by a net-like or mesh-like structure characterised by a net-like or mesh-like structure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F2210/00—Particular material properties of prostheses classified in groups A61F2/00 - A61F2/26 or A61F2/82 or A61F9/00 or A61F11/00 or subgroups thereof
- A61F2210/0014—Particular material properties of prostheses classified in groups A61F2/00 - A61F2/26 or A61F2/82 or A61F9/00 or A61F11/00 or subgroups thereof using shape memory or superelastic materials, e.g. nitinol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F2210/00—Particular material properties of prostheses classified in groups A61F2/00 - A61F2/26 or A61F2/82 or A61F9/00 or A61F11/00 or subgroups thereof
- A61F2210/0061—Particular material properties of prostheses classified in groups A61F2/00 - A61F2/26 or A61F2/82 or A61F9/00 or A61F11/00 or subgroups thereof swellable
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F2210/00—Particular material properties of prostheses classified in groups A61F2/00 - A61F2/26 or A61F2/82 or A61F9/00 or A61F11/00 or subgroups thereof
- A61F2210/0076—Particular material properties of prostheses classified in groups A61F2/00 - A61F2/26 or A61F2/82 or A61F9/00 or A61F11/00 or subgroups thereof multilayered, e.g. laminated structures
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F2230/00—Geometry of prostheses classified in groups A61F2/00 - A61F2/26 or A61F2/82 or A61F9/00 or A61F11/00 or subgroups thereof
- A61F2230/0002—Two-dimensional shapes, e.g. cross-sections
- A61F2230/0004—Rounded shapes, e.g. with rounded corners
- A61F2230/0008—Rounded shapes, e.g. with rounded corners elliptical or oval
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F2230/00—Geometry of prostheses classified in groups A61F2/00 - A61F2/26 or A61F2/82 or A61F9/00 or A61F11/00 or subgroups thereof
- A61F2230/0002—Two-dimensional shapes, e.g. cross-sections
- A61F2230/0017—Angular shapes
- A61F2230/0021—Angular shapes square
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F2230/00—Geometry of prostheses classified in groups A61F2/00 - A61F2/26 or A61F2/82 or A61F9/00 or A61F11/00 or subgroups thereof
- A61F2230/0002—Two-dimensional shapes, e.g. cross-sections
- A61F2230/0017—Angular shapes
- A61F2230/0026—Angular shapes trapezoidal
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F2230/00—Geometry of prostheses classified in groups A61F2/00 - A61F2/26 or A61F2/82 or A61F9/00 or A61F11/00 or subgroups thereof
- A61F2230/0063—Three-dimensional shapes
- A61F2230/0067—Three-dimensional shapes conical
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F2250/00—Special features of prostheses classified in groups A61F2/00 - A61F2/26 or A61F2/82 or A61F9/00 or A61F11/00 or subgroups thereof
- A61F2250/0014—Special features of prostheses classified in groups A61F2/00 - A61F2/26 or A61F2/82 or A61F9/00 or A61F11/00 or subgroups thereof having different values of a given property or geometrical feature, e.g. mechanical property or material property, at different locations within the same prosthesis
- A61F2250/0039—Special features of prostheses classified in groups A61F2/00 - A61F2/26 or A61F2/82 or A61F9/00 or A61F11/00 or subgroups thereof having different values of a given property or geometrical feature, e.g. mechanical property or material property, at different locations within the same prosthesis differing in diameter
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F2250/00—Special features of prostheses classified in groups A61F2/00 - A61F2/26 or A61F2/82 or A61F9/00 or A61F11/00 or subgroups thereof
- A61F2250/0058—Additional features; Implant or prostheses properties not otherwise provided for
- A61F2250/0067—Means for introducing or releasing pharmaceutical products into the body
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F2250/00—Special features of prostheses classified in groups A61F2/00 - A61F2/26 or A61F2/82 or A61F9/00 or A61F11/00 or subgroups thereof
- A61F2250/0058—Additional features; Implant or prostheses properties not otherwise provided for
- A61F2250/0096—Markers and sensors for detecting a position or changes of a position of an implant, e.g. RF sensors, ultrasound markers
- A61F2250/0098—Markers and sensors for detecting a position or changes of a position of an implant, e.g. RF sensors, ultrasound markers radio-opaque, e.g. radio-opaque markers
Definitions
- the invention relates to the technical field of medical devices, in particular to a blood vessel stent.
- Intracranial aneurysms are mostly abnormal bulges on the walls of intracranial arteries and are the leading cause of subarachnoid hemorrhage. three. The disease can occur at any age, and most commonly occurs in middle-aged and elderly women between the ages of 40 and 60. The etiology of intracranial aneurysm is still unclear. Most researchers believe that intracranial aneurysm is caused by local congenital defects of the intracranial artery wall and increased intraluminal pressure. Hypertension, cerebral arteriosclerosis, vasculitis and The occurrence and development of aneurysms are related. Intracranial aneurysms usually occur in the basilar artery ring (Circle of Willis), of which 80% occur in the anterior half of the basilar artery ring.
- the imaging of the existing braided stent is usually realized by splicing radiopaque development points on the stent body, radiopaque hybrid weaving, etc., which is only partial visualization.
- curved blood vessels affected by the braiding pitch of the stent, it is impossible to judge whether the stent adheres to the wall through a small number of developing wires; in the variable diameter blood vessel, the pitch of the stent will change correspondingly with the change of the diameter of the blood vessel, and the doctor does not have the confidence to judge whether it is fully opened.
- the technical problem to be solved by the present invention is to provide a vascular stent, which can be visualized as a whole, the boundary of the vascular stent can be seen during the operation, and the doctor can clearly judge whether the vascular stent adheres to the wall and has a high supporting force.
- the technical solution adopted by the present invention to solve the above technical problems is to provide a vascular stent, the vascular stent is a self-expanding braided tube formed by cross-braiding at least one first braided wire and a combined braided wire, wherein: each The first braided wire comprises a first core wire and a sleeve wrapped outside the first core wire; and the combined braided wire is composed of at least one of the first braided wire and at least one second braided wire formed together.
- the blood vessel stent is a self-expanding braided tube formed by the blood vessel stent being helically cross-braided by the at least one first braided wire and the combined braided wire.
- the blood vessel stent is a self-expanding braided tube formed by the at least one first braided wire and the combined braided wire from both ends of the blood vessel stent in a clockwise direction and a counterclockwise direction respectively.
- the cannula is made of an elastic biomaterial
- the first core wire is made of a radiopaque material
- the linear attenuation coefficient of the material of the first core wire is greater than the linear attenuation coefficient of the material of the cannula attenuation coefficient
- the opaque material is one of platinum, iridium, gold, silver and tantalum or an alloy thereof
- the elastic biological material is nickel-titanium alloy, nitinol, stainless steel, cobalt-chromium alloy, nickel-cobalt alloy one or more of.
- the cross-sectional shape of the first braided wire is a circle, a square, an ellipse or a trapezoid.
- the cross-sectional area of the first core wire accounts for 10% to 40% of the total cross-sectional area of the first braided wire.
- the second braided wire includes a second core wire and a radiopaque wire wound on the second core wire.
- the wire attenuation coefficient of the material with the largest wire attenuation coefficient is not more than 25 times the wire attenuation coefficient of the material with the smallest wire attenuation coefficient.
- the linear attenuation coefficient of the opaque wire does not exceed 25 times the linear attenuation coefficient of the first core wire.
- the cross-sectional shape of the second braided wire is a circle, a square, an ellipse or a trapezoid.
- the opaque wire is one of platinum, iridium, gold, silver and tantalum or an alloy thereof, and the second core wire is a nickel-titanium alloy or the first braided wire.
- the axial distance L between two adjacent coils of the opaque wire wound on the second core wire is 1.0-1.5 times the diameter of the opaque wire.
- the number of the first braiding wires is 24-96, and the number of the second braiding wires is 2-6.
- the surface of the first braided wire or/and the second braided wire is sprayed or leached with a drug coating, an antithrombotic coating or/and a hydrophilic coating.
- the self-expanding braided tube in a contracted state, has a first diameter, and the first diameter is less than 0.74 mm; in an expanded state, the self-expanding braided tube has a second diameter, and the second diameter It is 1.5mm ⁇ 7mm, and the expansion force from the first diameter to the second diameter is not less than 0.01N ⁇ 1N.
- the cross-sectional diameter of the second braided wire is no greater than 90 ⁇ m, and the cross-sectional diameter of the first braided wire is no greater than 50 ⁇ m.
- the first diameter of the self-expanding braided tube is less than 0.6858mm, wherein the cross-sectional diameter of the second braided wire is no greater than 80 ⁇ m, and the cross-sectional diameter of the first braided wire is no greater than 45 ⁇ m.
- the first diameter of the self-expanding braided tube is less than 0.5334mm, wherein the cross-sectional diameter of the second braided wire is no greater than 50 ⁇ m, and the cross-sectional diameter of the first braided wire is no greater than 35 ⁇ m .
- the diameter of the self-expanding braided tube is less than 0.4826 mm, wherein the diameter of the second braided wire is no greater than 30 ⁇ m, and the diameter of the first braided wire is no greater than 30 ⁇ m.
- the self-expanding braided tube in the expanded state, includes a first end, a middle section and a second end in sequence, the middle section of the self-expanding braided tube has the same outer diameter, and all the self-expanding braided tubes have the same outer diameter.
- the outer diameters of the first end and the second end gradually increase from the middle section to the port direction of the self-expanding braided tube.
- the length of the middle section in the axial direction is 2 mm to 60 mm
- the length of the first end and the second end in the axial direction are both 0.5 to 3 mm
- the length of the first end or the second end is 0.5 to 3 mm.
- the included angle formed by the busbar of the portion where the outer diameter of both ends gradually increases from the middle section to the port direction of the self-expanding braided tube and the central axis direction of the self-expanding braided tube is 10° ⁇ 60°.
- first end and the second end of the self-expanding braided tube are flared, truncated, beveled or star-shaped in cross-section of the first end and the second end.
- the length of the self-expanding braided tube in the axial direction is 2-70 mm, and the included angles formed by the two groups of braided wires in the cross-braided axial direction and the circumferential direction are 100°-140° and 40° respectively. ⁇ 80°.
- the present invention has the following beneficial effects: the blood vessel stent provided by the present invention is cross-braided into a self-expanding braided tube by the first braided wire composed of a radiopaque material and a shape memory alloy, and the stent as a whole and each braided tube are cross-braided.
- the filaments can be visualized and have a shape memory effect, which can self-expand to a predetermined size; the radiopaque core can be visualized under DSA, and the border of the vascular stent can be clearly seen during the operation, and the doctor can clearly determine whether the vascular stent adheres to the wall;
- the second braided wire with stronger opacity is added, which is more visible under X-ray than other braided wires, and is placed opposite in the circumferential direction. According to the distance between the two sides of the circumference, the opening of the head end of the vascular stent can be judged Diameter, whether there is a fish mouth.
- FIG. 1 is a schematic diagram of the overall structure of a blood vessel stent in an embodiment of the present invention
- FIG. 2 is a schematic cross-sectional view of a first braided wire in an embodiment of the present invention
- FIG. 3 is a schematic cross-sectional view of the second braided wire in the embodiment of the present invention.
- FIG. 1 is a schematic diagram of the overall structure of a blood vessel stent in an embodiment of the present invention
- FIG. 2 is a schematic cross-sectional view of a first braided wire in an embodiment of the present invention.
- the blood vessel stent provided in this embodiment is a self-expanding braided tube formed by cross-braiding the first component and the second component, or the blood vessel stent is formed by cross-braiding the second component entirely.
- Self-expanding braided tube in a preferred embodiment, the blood vessel stent is a self-expanding braided tube formed by helical cross braiding of the first component and the second component, and further, the blood vessel stent is made of the first component and the second component.
- the first component includes at least one first braided wire 11, and the first braided wire 11 includes a first core wire 111 and a sleeve 112 covering the outside of the first core wire 111;
- the first The core wire 111 is made of an opaque material, which can be platinum, iridium, gold, silver, tantalum and its alloys, etc.;
- the sleeve 112 is made of an elastic biomaterial, and the elastic biomaterial is one or more of nickel-titanium alloy, nitinol, stainless steel, cobalt-chromium alloy, and nickel-cobalt alloy, the linear attenuation coefficient of the material of the first core wire 111 is higher than the linear attenuation coefficient of the sleeve 112, the first The core wire 111 is more opaque.
- the cross-section of the first braided wire 11 can be circular, square, oval or trapezoidal, etc.
- the cross-section of the first braided wire 11 is circular; wherein the cross-sectional area of the first core wire 111 accounts for the 10% to 40% of the total cross-sectional area; preferably, the cross-sectional area of the first core wire 111 accounts for 30% of the total cross-sectional area of the first braided wire 11 .
- the second component includes at least one first braided wire 11 and at least one second braided wire 12 .
- the second braided wire 12 includes a second core wire 121 and an opaque wire 122 wound on the second core wire 121.
- the opaque wire 122 can be made of platinum, iridium, gold, silver, tantalum and alloys thereof.
- the material of the second core wire 121 is preferably a nickel-titanium alloy, or the first braided wire 11 is used as the second core wire 121 .
- each second braided wire 12 is combined with a first braided wire 11 to form a combined braided wire 1 and then spirally cross-braided with the first component.
- the linear attenuation coefficient of the radiopaque wire 122 is greater than the linear attenuation coefficient of the second core wire 121 .
- Each material has a linear attenuation coefficient / linear absorption coefficient ⁇ l (linear absorption coefficient), the linear attenuation coefficient ⁇ l is obtained by the mathematical product of the mass attenuation coefficient ⁇ m and the density ⁇ of the material itself. The higher the linear attenuation coefficient, the greater the opacity.
- the linear attenuation coefficient of the material with the largest linear attenuation coefficient does not exceed 25 times the linear attenuation coefficient of the material with the smallest linear attenuation coefficient
- the linear attenuation coefficient value of the opaque wire 122 is not more than 25 times the linear attenuation coefficient value of the first core wire 111 .
- the cross-section of the second braided wire 12 can be circular, square, oval or trapezoidal, etc.
- the cross-section of the second braided wire 12 is circular; please refer to FIG. 3 , preferably, the second core wire is wound around the second core wire
- the axial distance L between two adjacent effective coils of the opaque wire 122 on 121 is 1.0-1.5 times the wire diameter of the opaque wire 122 . More preferably, the axial distance L between two adjacent effective coils of the opaque wire 122 is 1.0-1.2 times the wire diameter of the opaque wire 122 .
- the quantity of the second braided wires 12 constituting the self-expanding braided tube is smaller than the quantity of the first braided wires 11 .
- the number of the first braided wires 11 is preferably 24-96, and the number of the second braided wires 12 is preferably 2-6; more preferably, the number of the first braided wires 11 is 44-62, and the second braided wires 12 The number is 2 to 4; preferably, when the self-expanding braided tube is in a stretched state, the first braided wires 11 and the second braided wires 12 are evenly distributed in the circumferential direction.
- first braided wire 11 and the second braided wire 12 can be sprayed or leached with a drug coating, an antithrombotic coating or/and a hydrophilic coating, etc. as required.
- the vascular stent has better use and performance.
- the self-expanding braided tube has a first diameter in a contracted state and a second diameter in a distracted state, the self-expanding braided tube being transportable by the delivery catheter in a state having the first diameter
- the lesion When the lesion is expanded to a second diameter, where the first diameter is less than 0.74mm, it can be delivered through a catheter with an inner diameter of 0.029 inches or less, and the second diameter can be expanded to 1.5mm to 7mm.
- the silks all contain elastic materials, the expansion force of the self-expanding braided tube from the first diameter to the second diameter is 0.01N ⁇ 1N, and the expanded blood vessel stent has a high supporting force.
- each braided wire constituting the stent contains a radiopaque material and an elastic material, the entire vascular stent and each braided wire can be visualized, and has a shape memory effect, and can self-expand to a predetermined size. Size; the first core wire 111 made of opaque material can be seen under DSA (angiography), the boundary of the vascular stent can be clearly seen during the operation, and the doctor can clearly judge whether the vascular stent adheres to the wall.
- DSA angiography
- the size in the axial direction of the mesh 3 formed by the helical cross braiding of the first braided wire 11 and the combined braided wire 1 of the self-expanding braided tube is preferably 0.1 mm to 1 mm; preferably, the axial size is 0.1 mm to 0.5 mm .
- the mesh size can be controlled by the number of braided wires and the braiding angle.
- the length of the self-expanding braided tube in the axial direction is 2-70 mm
- the included angles formed by the two groups of braided wires in the cross-braided axial direction and the circumferential direction are 100°-140° and 40° respectively. ⁇ 80°.
- the included angles formed by the cross-braided two groups of braided filaments in the axial direction and the circumferential direction are 110° ⁇ 130° and 50° ⁇ 70°, respectively.
- the metal coverage in the self-expanding braided tube is 20% to 40%, preferably, the metal coverage is 25% to 35%.
- the metal coverage refers to the percentage of the surface area of the metal wires forming the self-expanding braided tube to the surface area of the entire self-expanding braided tube.
- the self-expanding braided tube In the expanded state, the self-expanding braided tube includes a first end 22, a middle section 21 and a second end 23 in sequence, the middle section 21 of the self-expanding braided tube has the same outer diameter, and the self-expanding braided tube has the same outer diameter.
- the outer diameters of the first end 22 and the second end 23 gradually increase from the middle section 21 to the port direction of the self-expanding braided tube. That is, the outer diameter d2 of the ports of the first end 22 and the second end 23 is larger than the diameter d1 of the middle section 21, and the first end 22 and the second end 23 may be flared as shown in FIG.
- the flared shape can also be in the shape of a truncated cone, a slope, or the like, or the cross-sections of the first end 22 and the second end 23 are in a star shape, which is not particularly limited in the present invention.
- the length of the first end 22 and the second end 23 in the axial direction is preferably 0.5 to 3 mm, and the busbar that constitutes the rotating body of the first end 22 or the second end 23 forms 10 to 60° in the direction of the central axis of the self-expanding braided tube.
- the included angle preferably, the included angle ⁇ in the direction of the central axis of the self-expanding braided tube and the generatrix forming the rotating body of the first end 22 and the second end 23 is 30-60°.
- the included angle ⁇ in the direction of the central axis of the self-expanding braided tube and the generatrix forming the rotating body of the first end 22 and the second end 23 is 30-45°
- the self-expanding braid can be compressed to a first diameter, and in one embodiment, is delivered to the site of the aneurysm through a 0.029-inch catheter, wherein the cross-sectional diameter of the second braided wire 12 is no greater than 90 ⁇ m, and the first The cross-sectional diameter of the braided wire 11 is not more than 50 ⁇ m.
- the diameter of the self-expanding braided tube in a compressed state is less than 0.027 inches, wherein the diameter of the second braided wire 12 is not greater than 80 ⁇ m, the first braided wire The diameter of 11 is not more than 45 ⁇ m.
- the diameter of the self-expanding braided tube in the compressed state is less than 0.021 inches, wherein the diameter of the second braided wire 12 is not greater than 50 ⁇ m, and the first braided wire 11 The diameter is not more than 35 ⁇ m.
- the diameter of the self-expanding braided tube in the compressed state is less than 0.017 inches, wherein the diameter of the second braided wire 12 is not greater than 30 ⁇ m, and the first braided wire 11 The diameter is not more than 30 ⁇ m.
- the vascular stent provided in this embodiment is a self-expanding braided tube formed by helical cross braiding of a first component and a second component, and the first component is a first braided wire 11.
- the second component is a combined braided wire 1 formed by combining the first braided wire 11 and the second braided wire 12 together.
- the first braided wire 11 includes a first core wire 111 and a sleeve 112 covering the outside of the first core wire 111, the first core wire 111 is made of platinum; the sleeve 112 is made of nickel-titanium alloy become.
- the second braided wire 12 includes a second core wire 121 and an opaque wire 122 wound on the second core wire 121.
- the opaque wire 122 is platinum, and the second core wire 121 is a nickel-titanium alloy.
- the linear attenuation coefficient of the first core wire 111 in the first braided wire 11 is 5148 cm ⁇ 1
- the linear attenuation coefficient of the sleeve 112 is 258 cm ⁇ 1
- the second braided wire 12 is opaque to the wire of the wire 122
- the attenuation coefficient is 5148 cm -1
- the linear attenuation coefficient of the second core wire 121 is 258 cm -1 .
- the ratio of the maximum linear attenuation coefficient to the minimum linear attenuation coefficient is about 20.
- the cross section of the second braided wire 12 is circular; please refer to FIG.
- the wire diameter of the first braided wire 11 is 45 ⁇ m, and the wire diameter of the second braided wire 12 is 85 ⁇ m, which can be compressed to a first diameter of 0.029 inches for delivery.
- the number of the first braided wires 11 is 44, and the number of the second braided wires 12 is 4; when the self-expanding braided tube is in a stretched state, the first braided wires 11 and the second braided wires 12 are arranged in a circumferential direction. Evenly distributed.
- the surfaces of the first braided wire 11 and the second braided wire 12 are sprayed with a drug coating.
- the self-expanding braided tube includes a first end 22, a middle section 21 and a second end 23 in sequence, the middle section 21 of the self-expanding braided tube has the same outer diameter, and the self-expanding braided tube has the same outer diameter.
- the outer diameters of the first end 22 and the second end 23 gradually increase from the middle section 21 to the port direction of the self-expanding braided tube. That is, the outer diameter d2 of the ports of the first end 22 and the second end 23 is larger than the diameter d1 of the middle section 21 , and the first end 22 and the second end 23 are flared as shown in FIG. 1 .
- the length of the first end 22 and the second end 23 in the axial direction is 0.5 mm.
- the angle ⁇ between the first end 22 and the second end 23 and the central axis direction of the self-expanding braided tube is 30°.
- the vascular stent provided in this embodiment is a self-expanding braided tube formed by helical cross braiding of a first component and a second component, and the first component is a first braided wire 11.
- the second component is a combined braided wire 1 formed by combining the first braided wire 11 and the second braided wire 12 together.
- the first braided wire 11 includes a first core wire 111 and a sleeve 112 wrapped around the first core wire 111, the first core wire 111 is made of platinum; the sleeve 112 is made of cobalt-chromium alloy become.
- the second braided wire 12 includes a second core wire 121 and an opaque wire 122 wound on the second core wire 121 , the opaque wire 122 is platinum, and the second core wire 121 is the first braided wire 11 .
- the linear attenuation coefficient of the first core wire 111 in the first braided wire 11 is 5148 cm ⁇ 1
- the linear attenuation coefficient of the sleeve 112 is 379 cm ⁇ 1
- the second braided wire 12 is opaque to the wire of the wire 122
- the attenuation coefficient was 5148 cm ⁇ 1
- the linear attenuation coefficient of the second core wire 121 was 952 cm ⁇ 1 .
- the ratio of the maximum linear attenuation coefficient to the minimum linear attenuation coefficient is about 14.
- the cross section of the second braided wire 12 is circular; please refer to FIG.
- the wire diameter of the first braided wire 11 is 40 ⁇ m, and the wire diameter of the second braided wire 12 is 75 ⁇ m, which can be compressed to a first diameter of 0.027 inches for delivery.
- the number of the first braided wires 11 is 46, and the number of the second braided wires 12 is 2; when the self-expanding braided tube is in a stretched state, the first braided wires 11 and the second braided wires 12 are arranged in a circumferential direction. Evenly distributed.
- the surfaces of the first braided wire 11 and the second braided wire 12 are sprayed with an antithrombotic coating.
- the vascular stent has better antithrombotic properties.
- the self-expanding braided tube In the expanded state, the self-expanding braided tube includes a first end 22, a middle section 21 and a second end 23 in sequence, the middle section 21 of the self-expanding braided tube has the same outer diameter, and the self-expanding braided tube has the same outer diameter.
- the outer diameters of the first end 22 and the second end 23 gradually increase from the middle section 21 to the port direction of the self-expanding braided tube. That is, the outer diameter d2 of the ports of the first end 22 and the second end 23 is larger than the diameter d1 of the middle section 21 , and the first end 22 and the second end 23 are flared as shown in FIG. 1 .
- the length of the first end 22 and the second end 23 in the axial direction is 0.5 mm.
- the angle ⁇ between the first end 22 and the second end 23 and the central axis direction of the self-expanding braided tube is 45°.
- the vascular stent provided in this embodiment is a self-expanding braided tube formed by helical cross braiding of a first component and a second component, and the first component is a first braided wire 11.
- the second component is a combined braided wire 1 formed by combining the first braided wire 11 and the second braided wire 12 together.
- the first braided wire 11 includes a first core wire 111 and a sleeve 112 covering the outside of the first core wire 111 .
- the first core wire 111 is made of tantalum; the sleeve 112 is made of cobalt-chromium alloy.
- the second braided wire 12 includes a second core wire 121 and a radiopaque wire 122 wound on the second core wire 121 , the radiopaque wire 122 is made of tantalum, and the second core wire 121 is the first braided wire 11 .
- the linear attenuation coefficient of the first core wire 111 in the first braided wire is 1671 cm ⁇ 1 , and the linear attenuation coefficient of the material of the sleeve 112 is 379 cm ⁇ 1 ; the linear attenuation of the opaque wire 122 in the second braided wire
- the coefficient is 1671 cm -1
- the linear attenuation coefficient of the second core wire 121 is 952 cm -1 .
- the ratio of the largest linear attenuation coefficient to the smallest linear attenuation coefficient is about 4.4.
- the cross section of the second braided wire 12 is circular; please refer to FIG.
- the wire diameter of the first braided wire 11 is 35 ⁇ m
- the wire diameter of the second braided wire 12 is 50 ⁇ m, which can be compressed to a first diameter of 0.021 inches for delivery.
- the number of the first braided wires 11 is 60, and the number of the second braided wires 12 is 4; when the self-expanding braided tube is in a stretched state, the first braided wires 11 and the second braided wires 12 are arranged in a circumferential direction. Evenly distributed.
- the surfaces of the first braided wire 11 and the second braided wire 12 are leached with a hydrophilic coating.
- the self-expanding braided tube In the expanded state, the self-expanding braided tube includes a first end 22, a middle section 21 and a second end 23 in sequence, the middle section 21 of the self-expanding braided tube has the same outer diameter, and the self-expanding braided tube has the same outer diameter.
- the outer diameters of the first end 22 and the second end 23 gradually increase from the middle section 21 to the port direction of the self-expanding braided tube. That is, the outer diameter d2 of the ports of the first end 22 and the second end 23 is larger than the diameter d1 of the middle section 21 , and the first end 22 and the second end 23 may be flared as shown in FIG. 1 .
- the length of the first end 22 and the second end 23 in the axial direction is 1.0 mm.
- the angle ⁇ between the first end 22 and the second end 23 and the central axis direction of the self-expanding braided tube is 60°.
- the vascular stent provided in this embodiment is a self-expanding braided tube formed by helical cross braiding of a first component and a second component, and the first component is a first braided wire 11.
- the second component is a combined braided wire 1 formed by combining the first braided wire 11 and the second braided wire 12 together.
- the first braided wire 11 includes a first core wire 111 and a sleeve 112 covering the outside of the first core wire 111 .
- the first core wire 111 is made of gold; the sleeve 112 is made of cobalt-chromium alloy.
- the second braided wire 12 includes a second core wire 121 and a radiopaque wire 122 wound on the second core wire 121 , the radiopaque wire 122 is made of tantalum, and the second core wire 121 is the first braided wire 11 .
- the linear attenuation coefficient of the first core wire 111 in the first braided wire is 3864 cm ⁇ 1 , and the linear attenuation coefficient of the material of the sleeve 112 is 379 cm ⁇ 1 ; the linear attenuation of the opaque wire 122 in the second braided wire
- the coefficient is 1671 cm -1
- the linear attenuation coefficient of the second core wire 121 is 952 cm -1 .
- the ratio of the maximum linear attenuation coefficient to the minimum linear attenuation coefficient is about 10.2.
- the cross section of the second braided wire 12 is circular; please refer to FIG.
- the wire diameter of the first braided wire 11 is 25 ⁇ m
- the wire diameter of the second braided wire 12 is 25 ⁇ m, which can be compressed to the first diameter and then delivered to the location of the aneurysm by a 0.017-inch catheter.
- the number of the first braided wires 11 is 62, and the number of the second braided wires 12 is 2; when the self-expanding braided tube is in a stretched state, the first braided wires 11 and the second braided wires 12 are arranged in a circumferential direction. Evenly distributed.
- the surfaces of the first braided wire 11 and the second braided wire 12 are leached with a drug coating.
- the self-expanding braided tube includes a first end 22, a middle section 21 and a second end 23 in sequence, the middle section 21 of the self-expanding braided tube has the same outer diameter, and the self-expanding braided tube has the same outer diameter.
- the outer diameters of the first end 22 and the second end 23 gradually increase from the middle section 21 to the port direction of the self-expanding braided tube. That is, the outer diameter d2 of the ports of the first end 22 and the second end 23 is larger than the diameter d1 of the middle section 21 , and the first end 22 and the second end 23 are flared as shown in FIG. 1 .
- the length of the first end 22 and the second end 23 in the axial direction is 2 mm; the angle ⁇ between the first end 22 and the second end 23 and the central axis direction of the self-expanding braided tube is 35°.
- a vascular stents employing 36 MP35N (a nickel-cobalt-chromium-molybdenum alloy) and a platinum wire 12 mixed woven, braided wire diameter of 30 m, a density MP35N material is 8.41g / cm 3 , platinum is 21.45g/cm 3 , under the condition of wavelength of 0.07107nm, the mass absorption coefficient of MP35N material is about 35 ⁇ 45cm 2 /g, and the mass absorption coefficient of platinum is 200 ⁇ 240cm 2 /g.
- MP35N a nickel-cobalt-chromium-molybdenum alloy
- platinum is 21.45g/cm 3
- the mass absorption coefficient of MP35N material is about 35 ⁇ 45cm 2 /g
- the mass absorption coefficient of platinum is 200 ⁇ 240cm 2 /g.
- the first braided wire 11 in Example 2 is helically woven, the diameter of the first braided wire 11 is 40 ⁇ m, the density is 13.6 g/cm 3 , and the mass absorption coefficient is 60-70 cm 2 /g.
- the second core wire 121 of the second braided wire 12 After adding the second braided wire, the second core wire 121 of the second braided wire 12 has a diameter of 35 ⁇ m, a density of 6.45 g/cm 3 , and a mass absorption coefficient of 30-40 cm 2 /g;
- the density of the silk 122 is 21.45 g/cm 3
- the mass absorption coefficient is 200-240 cm 2 /g
- the I I 0 e -24.24 of the second braided silk 12
- the visualization of the second braided silk 12 is obviously stronger than that of the vascular stent product
- the platinum wire used in A therefore, the visualization of the vascular stent provided in Example 2 is better than that of the vascular stent product A.
- the second braided wire 12 is more visible than other braided wires under X-ray, and is placed opposite to each other in the circumferential direction. According to the distance between the two sides of the circumference, the opening diameter of the end of the blood vessel stent can be determined, and whether there is a fish can be judged. Mouth situation appears.
- the vascular stent provided by the present invention has at least the following advantages:
- Each braided wire constituting the vascular stent contains opaque materials and elastic materials, the entire vascular stent and each braided wire can be visualized, and has a shape memory effect, which can self-expand to a predetermined size;
- the main body of the vascular stent is woven from the first braided wire of which the outer sleeve is made of elastic material and the first core wire of the inner layer is made of opaque material.
- the elastic material accounts for a large proportion, provides self-expansion force and has a large supporting force; the radiopaque core wire is visible under DSA, and the boundary of the vascular stent can be clearly seen during the operation, and the doctor can clearly determine whether the vascular stent adheres to the wall ;
- the added second braided silk has a more opaque material, the second braided silk is more developed than other braided silks under X-ray, and is placed opposite in the circumferential direction, according to the distance between the two sides of the circumference
- the opening diameter of the head end of the stent can be determined, and whether there is a fish mouth situation can be judged.
Landscapes
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Cardiology (AREA)
- Oral & Maxillofacial Surgery (AREA)
- Transplantation (AREA)
- Heart & Thoracic Surgery (AREA)
- Vascular Medicine (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Media Introduction/Drainage Providing Device (AREA)
Abstract
Description
Claims (26)
- 一种血管支架,其特征在于,所述血管支架为由至少一根第一编织丝和组合编织丝交叉编织形成的自膨胀编织管,其中:每根所述第一编织丝包括第一芯丝和包覆在所述第一芯丝外面的套管;以及所述组合编织丝由至少一根所述第一编织丝和至少一根第二编织丝组合在一起形成。
- 如权利要求1所述的血管支架,其特征在于,所述血管支架为由所述至少一根第一编织丝和所述组合编织丝螺旋交叉编织形成的自膨胀编织管。
- 如权利要求2所述的血管支架,其特征在于,所述血管支架为由所述至少一根第一编织丝和所述组合编织丝从所述血管支架的两端分别沿顺时针和逆时针的方向螺旋交叉编织形成的自膨胀编织管。
- 如权利要求1所述的血管支架,其特征在于,所述套管由弹性生物材料制成,所述第一芯丝由不透射性材料制成,且所述第一芯丝的材料的线衰减系数大于所述套管的材料的线衰减系数。
- 如权利要求4所述的血管支架,其特征在于,所述不透射性材料为铂、铱、金、银和钽中的一种或其合金,所述弹性生物材料为镍钛合金、镍钛诺、不锈钢、钴铬合金、镍钴合金的一种或多种。
- 如权利要求1所述的血管支架,其特征在于,所述第一编织丝的截面形状为圆形、方形、椭圆形或梯形。
- 如权利要求6所述的血管支架,其特征在于,所述第一芯丝的截面积占所述第一编织丝的总截面积的10%~40%。
- 如权利要求1所述的血管支架,其特征在于,每根所述第二编织丝包括第二芯丝和缠绕在所述第二芯丝上的不透射丝。
- 如权利要求8所述的血管支架,其特征在于,在组成所述第一编织丝和所述第二编织丝的所有材料中,最大线衰减系数的材料的线衰减系数不超过具有最小线衰减系数的材料的线衰减系数的25倍。
- 如权利要求9所述的血管支架,其特征在于,所述不透射丝的线衰 减系数不超过所述第一芯丝的线衰减系数的25倍。
- 如权利要求8所述的血管支架,其特征在于,所述第二编织丝的截面形状为圆形、方形、椭圆形或梯形。
- 如权利要求8所述的血管支架,其特征在于,所述不透射丝为铂、铱、金、银和钽中的一种或其合金,所述第二芯丝为镍钛合金或者为所述第一编织丝。
- 如权利要求8所述的血管支架,其特征在于,所述缠绕在所述第二芯丝上的不透射丝的两相邻线圈的轴向距离为所述不透射丝丝径的1.0~1.5倍。
- 如权利要求8所述的血管支架,其特征在于,所述第一编织丝的数量为24~96根,所述第二编织丝的数量为2~6根。
- 如权利要求8所述的血管支架,其特征在于,所述第一编织丝或/和所述第二编织丝表面喷涂或浸提有药物涂层、抗血栓涂层或/和亲水涂层。
- 如权利要求1所述的血管支架,其特征在于,在收缩状态下,所述自膨胀编织管具有第一直径,所述第一直径小于0.74mm;在撑开状态下,所述自膨胀编织管具有第二直径,所述第二直径为1.5mm~7mm。
- 如权利要求16所述的血管支架,其特征在于,所述自膨胀编织管由所述第一直径膨胀至所述第二直径的扩展力范围为0.01N~1N。
- 如权利要求16所述的血管支架,其特征在于,每根所述第一编织丝的截面直径不大于50μm,每根所述第二编织丝的截面直径不大于90μm。
- 如权利要求18所述的血管支架,其特征在于,在收缩状态下,所述自膨胀编织管的第一直径小于0.6858mm,其中每根所述第二编织丝的截面直径不大于80μm,每根所述第一编织丝的截面直径不大于45μm。
- 如权利要求18所述的血管支架,其特征在于,在收缩状态下,所述自膨胀编织管的第一直径小于0.5334mm,其中每根所述第二编织丝的截面直径为不大于50μm,每根所述第一编织丝的截面直径为不大于35μm。
- 如权利要求18所述的血管支架,其特征在于,在收缩状态下,所述自膨胀编织管的第一直径小于0.4826mm,其中每根所述第二编织丝的截面直径为不大于30μm,每根所述第一编织丝的截面直径为不大于30μm。
- 如权利要求1所述的血管支架,其特征在于,在撑开状态下,所述自膨胀编织管依次包括第一端、中间段和第二端,所述自膨胀编织管的中间段具有相同外径,所述自膨胀编织管的所述第一端和所述第二端从所述中间段向所述自膨胀编织管的端口方向的外径逐渐增大。
- 如权利要求22所述的血管支架,其特征在于,所述中间段在轴向上的长度为2mm~60mm,所述第一端和所述第二端在轴向上的长度均为0.5~3mm,所述第一端或所述第二端从所述中间段向所述自膨胀编织管的端口方向的外径逐渐增大的部分的母线与所述自膨胀编织管的中心轴方向上形成的夹角为10°~60°。
- 如权利要求22所述的血管支架,其特征在于,所述自膨胀编织管的所述第一端和所述第二端呈喇叭状、圆台状、斜坡口状,或所述第一端和所述第二端的横截面呈星形。
- 如权利要求1所述的血管支架,其特征在于,所述自膨胀编织管在轴向上的长度为2~70mm,所述交叉编织的两组编织丝在轴向上和周向上形成的夹角分别为100°~140°和40°~80°。
- 一种血管支架,其特征在于,所述血管支架为由至少一根所述第一编织丝和至少一根第二编织丝分交叉编织形成的自膨胀编织管,其中:每根所述第一编织丝包括第一芯丝和包覆在所述第一芯丝外面的套管。
Priority Applications (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2022581439A JP2023534403A (ja) | 2020-06-30 | 2021-08-13 | 血管ステント |
US18/013,718 US20240033111A1 (en) | 2020-06-30 | 2021-08-13 | Vascular stent |
EP21833784.8A EP4183376A4 (en) | 2020-06-30 | 2021-08-13 | VASCULAR STENT |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202010615047.4A CN113143555A (zh) | 2020-06-30 | 2020-06-30 | 一种血管支架 |
CN202010615047.4 | 2020-06-30 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2022002281A1 true WO2022002281A1 (zh) | 2022-01-06 |
Family
ID=76882221
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/CN2021/112630 WO2022002281A1 (zh) | 2020-06-30 | 2021-08-13 | 一种血管支架 |
Country Status (5)
Country | Link |
---|---|
US (1) | US20240033111A1 (zh) |
EP (1) | EP4183376A4 (zh) |
JP (1) | JP2023534403A (zh) |
CN (1) | CN113143555A (zh) |
WO (1) | WO2022002281A1 (zh) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN116211562A (zh) * | 2023-05-06 | 2023-06-06 | 北京久事神康医疗科技有限公司 | 一种凸点支架 |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN113143555A (zh) * | 2020-06-30 | 2021-07-23 | 微创神通医疗科技(上海)有限公司 | 一种血管支架 |
CN113925649A (zh) * | 2021-09-30 | 2022-01-14 | 艾柯医疗器械(北京)有限公司 | 自膨式血管支架 |
CN114287989B (zh) * | 2021-12-24 | 2023-12-08 | 珠海通桥医疗科技有限公司 | 一种血流导向装置支架 |
Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20030009215A1 (en) * | 1993-01-19 | 2003-01-09 | Schneider (Usa) Inc., A Minnesota Corporation | Clad composite stent |
CN102429750A (zh) * | 2011-08-15 | 2012-05-02 | 微创医疗器械(上海)有限公司 | 改进显影性能的血管支架及增强血管支架显影性能的方法 |
CN105125326A (zh) * | 2015-08-17 | 2015-12-09 | 魏诗荣 | 一种复合结构的血管内支架 |
CN205515056U (zh) * | 2016-03-15 | 2016-08-31 | 微创神通医疗科技(上海)有限公司 | 一种支架 |
CN212234823U (zh) * | 2020-06-30 | 2020-12-29 | 微创神通医疗科技(上海)有限公司 | 一种血管支架 |
CN113143555A (zh) * | 2020-06-30 | 2021-07-23 | 微创神通医疗科技(上海)有限公司 | 一种血管支架 |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5718159A (en) * | 1996-04-30 | 1998-02-17 | Schneider (Usa) Inc. | Process for manufacturing three-dimensional braided covered stent |
DE102013100984B4 (de) * | 2013-01-31 | 2019-03-21 | Acandis Gmbh | Gittergeflecht für ein medizinisches Implantat oder Instrument, Implantat und Instrument mit einem derartigen Gittergeflecht sowie Set mit einem solchen Implantat oder Instrument |
JP2021512717A (ja) * | 2018-02-08 | 2021-05-20 | コヴィディエン リミテッド パートナーシップ | 血管用拡張型デバイス |
US10456280B1 (en) * | 2018-08-06 | 2019-10-29 | DePuy Synthes Products, Inc. | Systems and methods of using a braided implant |
US20200046527A1 (en) * | 2018-08-08 | 2020-02-13 | András Kónya | Woven stent |
-
2020
- 2020-06-30 CN CN202010615047.4A patent/CN113143555A/zh active Pending
-
2021
- 2021-08-13 EP EP21833784.8A patent/EP4183376A4/en active Pending
- 2021-08-13 JP JP2022581439A patent/JP2023534403A/ja active Pending
- 2021-08-13 WO PCT/CN2021/112630 patent/WO2022002281A1/zh active Application Filing
- 2021-08-13 US US18/013,718 patent/US20240033111A1/en active Pending
Patent Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20030009215A1 (en) * | 1993-01-19 | 2003-01-09 | Schneider (Usa) Inc., A Minnesota Corporation | Clad composite stent |
CN102429750A (zh) * | 2011-08-15 | 2012-05-02 | 微创医疗器械(上海)有限公司 | 改进显影性能的血管支架及增强血管支架显影性能的方法 |
CN105125326A (zh) * | 2015-08-17 | 2015-12-09 | 魏诗荣 | 一种复合结构的血管内支架 |
CN205515056U (zh) * | 2016-03-15 | 2016-08-31 | 微创神通医疗科技(上海)有限公司 | 一种支架 |
CN212234823U (zh) * | 2020-06-30 | 2020-12-29 | 微创神通医疗科技(上海)有限公司 | 一种血管支架 |
CN113143555A (zh) * | 2020-06-30 | 2021-07-23 | 微创神通医疗科技(上海)有限公司 | 一种血管支架 |
Non-Patent Citations (1)
Title |
---|
See also references of EP4183376A4 * |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN116211562A (zh) * | 2023-05-06 | 2023-06-06 | 北京久事神康医疗科技有限公司 | 一种凸点支架 |
CN116211562B (zh) * | 2023-05-06 | 2023-11-21 | 北京久事神康医疗科技有限公司 | 一种凸点支架 |
Also Published As
Publication number | Publication date |
---|---|
US20240033111A1 (en) | 2024-02-01 |
JP2023534403A (ja) | 2023-08-09 |
EP4183376A1 (en) | 2023-05-24 |
CN113143555A (zh) | 2021-07-23 |
EP4183376A4 (en) | 2024-03-27 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2022002281A1 (zh) | 一种血管支架 | |
CN212234823U (zh) | 一种血管支架 | |
US11679458B2 (en) | Devices, systems, and methods for treating aneurysms | |
US12076022B2 (en) | Occlusion device | |
US20240032939A1 (en) | Occlusion Device | |
JP4825883B2 (ja) | 編込二又および三又ステントおよびその製造方法 | |
US20060200234A1 (en) | Endovascular aneurysm treatment device and delivery system | |
KR20120123121A (ko) | 동맥류 수술장치 | |
WO2022156095A1 (zh) | 新型密网支架 | |
WO2013097759A1 (zh) | 编织支架 | |
WO2023020353A1 (zh) | 一种医疗支架 | |
CN114052820A (zh) | 一种血管支架 | |
CN114287989A (zh) | 一种血流导向装置支架 | |
CN209966659U (zh) | 一种新型血管支架 | |
CN116211377B (zh) | 瘤内扰流装置 | |
WO2022022143A1 (zh) | 一种载膜支架 | |
US11911259B2 (en) | Multi-layer folding flow diverters | |
CN215778371U (zh) | 用于血流导向支架系统的支架 | |
WO2020259709A1 (zh) | 覆膜支架 | |
CN116035640A (zh) | 医用植入物及制备方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 21833784 Country of ref document: EP Kind code of ref document: A1 |
|
ENP | Entry into the national phase |
Ref document number: 2022581439 Country of ref document: JP Kind code of ref document: A |
|
WWE | Wipo information: entry into national phase |
Ref document number: 18013718 Country of ref document: US |
|
ENP | Entry into the national phase |
Ref document number: 2021833784 Country of ref document: EP Effective date: 20221230 |
|
NENP | Non-entry into the national phase |
Ref country code: DE |